Axonics v. Medtronic: Federal Circuit Appeal Voluntarily Dismissed in 302 Days
Axonics, Inc. challenged the validity of Medtronic’s US8626314B2 — covering implantable medical leads with tine retention elements — at the Federal Circuit. The parties jointly agreed to dismiss the appeal under Fed. R. App. P. 42(b) after 302 days, with each side bearing its own costs and no merits ruling issued.
A Federal Circuit validity challenge withdrawn before any merits adjudication
Filed on 16 April 2024 at the Court of Appeals for the Federal Circuit, Case No. 24-1701 pitted Axonics, Inc. against Medtronic, Inc. in an appeal centred on the patentability of US8626314B2. That patent, titled to cover an implantable medical lead incorporating a plurality of tine elements, sits at the intersection of sacral neuromodulation device design — a competitive battleground where Axonics and Medtronic have clashed across multiple proceedings.
The appeal was voluntarily dismissed on 12 February 2025 pursuant to Fed. R. App. P. 42(b), following a joint agreement between the parties. The court’s order explicitly states that each side shall bear its own costs. Because dismissal was stipulated and no merits opinion was issued, the underlying validity question — whether the tine-element lead claims survive scrutiny — was not resolved on the public record of this proceeding.
At 302 days, the case closed faster than a typical Federal Circuit merits appeal, suggesting the parties reached an accommodation — potentially linked to parallel district court or PTAB proceedings — before full appellate briefing concluded. What drove that accommodation, and whether it reflects a broader licensing or settlement arrangement between Axonics and Medtronic, is not disclosed in the public docket.
Filing to Voluntary dismissal in 302 days
302 days — resolved before a merits briefing cycle typically concludes at the Federal Circuit
Voluntarily dismissed: what the Rule 42(b) order means for both parties
Rule 42(b) dismissal — no merits ruling, appeal ends by consent
Fed. R. App. P. 42(b) permits parties to dismiss an appeal by stipulation or on motion. Here, both Axonics and Medtronic agreed to end the proceeding. Crucially, no Federal Circuit panel reviewed the merits of the validity challenge, meaning the lower-level patentability determination — whatever it was — is neither affirmed nor reversed by this order. The dismissal is procedural only.
Procedural exit — no validity rulingThe public record is silent on re-filing rights
A voluntary dismissal under Rule 42(b) may or may not bar re-litigation depending on the parties’ agreement and any underlying PTAB or district court estoppel rules. The court order does not specify whether dismissal is with or without prejudice. Patent attorneys monitoring this dispute should note that the public record does not resolve this question, and estoppel consequences — if any — would flow from separate IPR or litigation rules, not from this order alone.
Prejudice status: not specifiedAxonics withdraws the appeal — validity attack paused or abandoned
As the appellant seeking to invalidate US8626314B2, Axonics’ decision to dismiss means its Federal Circuit challenge produced no ruling in its favour. Whether Axonics obtained commercial concessions through a parallel negotiation — or simply concluded the appeal was no longer strategically necessary — is not apparent from the docket. The patent remains intact from this proceeding’s perspective.
No invalidity ruling securedMedtronic’s tine-element lead patent survives this challenge unchallenged on merits
Medtronic’s US8626314B2 exits this Federal Circuit proceeding without any adverse merits finding. The patent’s claims covering implantable leads with tine retention elements remain as-issued. For competitors and freedom-to-operate analysts, this means the patent’s enforceability posture is unchanged by this case — though prior PTAB or district court findings on the same patent, if any, would need separate review.
Patent status: unchanged by this caseFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axonics, Inc. | Company | Medical device company — challenger to validity of US8626314B2Search in Eureka ↗ |
| Defendant | Medtronic, Inc. | Company | Global medical device leader — holder of US8626314B2, implantable lead patentSearch in Eureka ↗ |
| Plaintiff counsel | Aaron Matthew Nathan | Attorney | Counsel for Axonics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Azra Hadzimehmedovic | Attorney | Counsel for Axonics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Matthew D. Powers | Attorney | Counsel for Axonics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Samantha A. Jameson | Attorney | Counsel for Axonics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William P. Nelson | Attorney | Counsel for Axonics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Tensegrity Law Group LLP | Law Firm | Representing Axonics, Inc.Search in Eureka ↗ |
| Defendant counsel | Chetan Bansal | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Naveen Modi | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant law firm | Paul Hastings, LLP | Law Firm | Representing Medtronic, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The order’s operative language — ‘DISMISSED under Fed. R. App. P. 42(b)’ — confirms a consensual procedural termination with no substantive adjudication. The Federal Circuit issued no opinion on the patentability merits of US8626314B2. The equal costs allocation reinforces that neither party extracted a legal concession through this proceeding. Any downstream implications for claim validity or enforceability must be assessed through other proceedings, not this order.
US8626314B2 — Implantable medical lead with tine retention elements
US8626314B2, filed under application number US13/183289, protects an implantable medical lead design incorporating a plurality of tine elements — flexible anchoring structures that secure the lead at the implant site following sacral neuromodulation placement. The tine configuration is a technically critical feature: it determines long-term lead stability without surgical fixation sutures, directly affecting patient outcomes and device revision rates.
In the competitive sacral neuromodulation market — where Medtronic’s InterStim system and Axonics’ r-SNM device compete directly — lead design patents like US8626314B2 represent meaningful barriers. Control over tine-element geometry and material configurations can influence which competitors can enter the market with comparable minimally invasive implant procedures. This patent’s survival through this Federal Circuit proceeding, unchallenged on the merits, leaves its enforceability posture intact for Medtronic.
Should your team run an FTO against US8626314B2?
Any organisation developing, manufacturing, or commercialising implantable leads for sacral neuromodulation, spinal cord stimulation, or adjacent indications should assess exposure to US8626314B2. The patent’s tine-element claims potentially read on any lead design using flexible retention structures for anchoring. Because this Federal Circuit appeal closed without a merits ruling, there is no new claim construction or invalidity finding to rely on as a design-around basis.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map claim language from US8626314B2 against current lead designs, identify prior art that was not resolved in this proceeding, and benchmark against the broader Medtronic neuromodulation patent family. Running a structured FTO now — before design lock or regulatory submission — is the most cost-effective way to manage exposure in this technology space.
Run a freedom-to-operate analysis on US8626314B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in implantable neuromodulation patent disputes
Cases involving validity challenges to implantable medical lead and neuromodulation device patents at the Federal Circuit, with comparable procedural histories.
What this case signals for the implantable neuromodulation IP landscape
A stipulated Federal Circuit dismissal in a validity dispute between two neuromodulation rivals rarely tells the full story.
Voluntary Federal Circuit dismissals often signal parallel deal-making
When both parties agree to drop a Federal Circuit validity appeal before merits briefing concludes, it typically suggests that the underlying commercial dispute has been addressed elsewhere — through a licence, a cross-licence, or a settlement that resolves multiple concurrent proceedings. Practitioners should check whether related PTAB or district court actions involving US8626314B2 closed around the same time.
No costs order preserves negotiating parity — a deliberate signal
The each-side-bears-own-costs term is consistent with a negotiated outcome rather than one party capitulating. In Federal Circuit practice, a prevailing party typically seeks costs; the mutual waiver here suggests neither side viewed itself as the clear winner, or that the broader deal made cost allocation irrelevant. IP teams tracking Axonics–Medtronic dynamics should treat this as a parity signal.
Axonics v Medtronic — key questions answered
The appeal was voluntarily dismissed by joint agreement of the parties under Fed. R. App. P. 42(b) on 12 February 2025. No merits ruling was issued on the patentability of US8626314B2. Each side was ordered to bear its own costs. The case lasted 302 days from filing to closure.
The dismissal is purely procedural. The Federal Circuit issued no opinion on whether US8626314B2’s claims are valid or invalid. The patent’s legal status is unchanged by this order. Any prior PTAB or district court findings on the patent’s validity remain the operative record for enforceability purposes.
The court order does not specify whether the dismissal is with or without prejudice. The public record is silent on this point. Whether Axonics retains any right to re-file a similar challenge would depend on the terms of any underlying settlement agreement and applicable PTAB estoppel rules, neither of which are disclosed in the docket.
The patent at issue is US8626314B2, application number US13/183289. It covers an implantable medical lead incorporating a plurality of tine elements — flexible retention structures used to anchor leads at the implant site in sacral neuromodulation procedures. The patent is held by Medtronic, Inc.
Axonics was represented by Tensegrity Law Group LLP, with counsel including Matthew D. Powers, Azra Hadzimehmedovic, Aaron Matthew Nathan, Samantha A. Jameson, and William P. Nelson. Medtronic was represented by Paul Hastings, LLP, with counsel Naveen Modi and Chetan Bansal.
PatSnap Eureka searches patents and litigation data to answer instantly.